Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05674929 | An Open-Label, Single Dose Study in Patients With Alcohol Use Disorder | PHASE2 | COMPLETED | 13 | — | — | May 30, 2023 | Oct 2, 2024 | Aug 14, 2025 | 2 | United Kingdom |
Measure the frequency, emotional valence and functional impact of any re-activation events in the study
| Arm | Type | Description |
|---|---|---|
| BPL-003 arm | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BPL-003 | DRUG | A single dose administered intranasally |
Inclusion Criteria: 1. Willing and able to give informed consent. 2. Age 18 to 64 years at Screening. 3. Diagnosed with moderate to severe AUD. 4. Minimum of 4 heavy drinking days in the 28 days before Screening. 5. No more than 14 days have elapsed since the last HDD or completion of detoxificatio...